- Home
- TPST vs APLT Comparison
TPST vs APLT Comparison
Compare TPST & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | APLT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 18.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TPST | APLT |
|---|---|---|
| Price | $2.71 | $0.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $1.25 |
| AVG Volume (30 Days) | 75.6K | ★ 11.6M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.40 | $0.09 |
| 52 Week High | $13.13 | $1.50 |
Technical Indicators
Market Signals| Indicator | TPST | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 28.21 |
| Support Level | $2.40 | $0.09 |
| Resistance Level | $3.03 | $0.10 |
| Average True Range (ATR) | 0.18 | 0.01 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 51.00 | 34.74 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.